Skip to main content

Posts tagged with "The Dark Side"

  • Cardiovascular Disease

    The New England Journal And Its PR Flacks

    The Wall Street Journal ran an interesting article by David Armstrong the other day on the New England Journal of Medicine and the Merck/Vioxx affair. It’s subscriber-only on the WSJ site, but the Pittsburgh Post-Gazette picked it up here. It brings up an angle that I hadn’t completely considered: While Merck has taken the brunt… Read More
  • Drug Industry History

    Serono’s Suitors

    If you stopped one hundred people on the street and asked them to name a drug company, I’d be astonished if a single one of them mentioned Serono. But they’re one of the largest biotechs in the world, even though their profile is low. Being a privately held (indeed, family-owned) concern surely has something to… Read More
  • Clinical Trials

    This Had Better Be Good

    I wrote a brief wrap-up on the FDA’s concerns about the new Bristol-Meyers Squibb / Merck diabetes drug Pargluva (muraglitazar). It’s officially “approvable”, but the FDA wants more cardiovascular safety data before it can be sold. But just this morning the JAMA web site has rushed out an article from a team at the Cleveland… Read More
  • The Dark Side

    Ghostly Influences

    Via Matthew Herper at Forbes, here’s a real grit-your-teeth article on the ghostwriting of journal articles from inside my industry. Now, I know that this stuff has been going on for a long time in the medical world, and I know that it happens constantly with newspaper op-ed pieces. It’s a growing trend/problem in the… Read More
  • Drug Prices

    So What’s Wrong With A Little Money Changing Hands?

    The marketing practices mentioned in the last posting sound a lot like radio-station payola – paying to get a song on the air. There was an interesting defense of this practice mounted recently over at Marginal Revolution (see the first three postings here. Is there a difference in this case? (I mean, short of the… Read More
  • The Dark Side

    No Defense

    In case anyone has me pegged as a reliable apologist for the pharmaceutical industry, I’d like to direct you to this article in the Sunday New York Times. It details marketing practices (in this case, from Schering-Plough) that, if reported accurately, amount to little more than programmatic bribery of physicians. I can’t defend this st… Read More
  • The Dark Side

    No Better Than the Rest of Them

    I noticed this post over at A Scientist’s Life on some recent instances of retracted papers and scientific fraud. Those two phenomena aren’t linked in every case, but they’re often seen in each other’s company. People do tend to think they’re a couple. The papers were from Science and Cell, two of the really top-shelf… Read More
  • The Dark Side

    Silver Tongues, Golden Hands?

    I’ve been thinking more about Sam Waksal’s interesting career (see the September 29 post below, and this link for an online version of the story – thanks to Charles Murtaugh for coming up with it.) What I’m specifically wondering about is the phenomenon of the silver-tongued hot-talking scientist that he represents. Charles… Read More
  • The Dark Side

    A Rake’s Progress

    Friday’s Wall Street Journal has an extraordinary front-page story on the career of Sam Waksal, late of Imclone. If you haven’t heard, it turns out that at every stage in his research career, these pesky. . .questions arose, bred by these nagging. . .doubts that what he was saying about his work was true. The… Read More